Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 38Thoracic 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 1432Pancreatic Neoplasms 860Carcinoma, Hepatocellular 743Stomach Neoplasms 647Colonic Neoplasms 447Rectal Neoplasms 404Esophageal Neoplasms 398Breast Neoplasms 331Carcinoma, Non-Small-Cell Lung 326Neoplasms 307Liver Neoplasms 282Cholangiocarcinoma 244Ovarian Neoplasms 243Lung Neoplasms 237Neoplasm Metastasis 235Gastrointestinal Neoplasms 217Melanoma 185Prostatic Neoplasms 166Esophageal Squamous Cell Carcinoma 166Biliary Tract Neoplasms 161Endometrial Neoplasms 143Uterine Cervical Neoplasms 130Squamous Cell Carcinoma of Head and Neck 129Carcinoma, Renal Cell 114Head and Neck Neoplasms 113Sarcoma 100Urinary Bladder Neoplasms 97Adenocarcinoma Of Esophagus 90Triple Negative Breast Neoplasms 86Anus Neoplasms 83

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-positive Breast Cancer × Gastrointestinal × 1 year × Clear all
NCT05514717 2025-07-11

A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

Mersana Therapeutics

Phase 1 Recruiting
162 enrolled
BreastGastrointestinalThoracic

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡